HCV patients with residual fibrosis after DAA treatment re-establish their epigenetic signature after prolonged-release pirfenidone: MINERVA study

Abstract Background & Aims Patients with residual liver fibrosis after hepatitis C virus infection clearance represent an important challenge. The primary objective of this study was to evaluate epigenetic marks in DAA-responders HCV, Hispanic patients with remaining fibrosis who were treated with p...

Descrición completa

Detalles Bibliográficos

Principais autores:	Eira Cerda-Reyes, Ricardo de la Rosa-Bibiano, Ana Sandoval-Rodriguez, Rebeca Rosas-Campos, Aldo Torre, Stefanny Cornejo-Hernández, Rebeca Escutia-Gutiérrez, Ángel Vázquez-Esqueda, Jorge Gutierrez-Cuevas, Alejandro Gutiérrez-Átemis, Salvador Amezquita-Pérez, Jorge Luis Poo, Gildardo Agustin Garrido-Sánchez, Javier Bastida-Alquicira, Elsa Saldaña-Rivera, Lucila Maritza Lozano-Trenado, Juan Ramón-Aguilar, Jose Alejandro Madrigal, Juan Armendariz-Borunda
Formato:	Artigo
Idioma:	Inglês
Publicado:	BMC 2025-10-01
Series:	Clinical Epigenetics
Assuntos:	Pirfenidone HCV-liver fibrosis Epigenetics miRNAs
Acceso en liña:	https://doi.org/10.1186/s13148-025-01969-y
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!